Table 8Blood tests compared with imaging

Study, YearCountryNProportion with Fibrosis or CirrhosisPopulation CharacteristicsDiagnosisAPRI: AUROC (95% CI)Imaging Findings: AUROC (95% CI)
Cobbold, 2009229UK67Fibrosis (Ishak ≥3): 55%
Cirrhosis (Ishak 5 or 6): 21%
Age: 50 years
Female: 34%
Genotype 1: Not reported
No current antiviral treatment
Excluded if >20 g alcohol/day
A: Fibrosis (Ishak ≥3)
B: Cirrhosis (Ishak 5–6)
APRI
A: 0.83 (0.73 to 0.93)
B: 0.86 (0.75 to 0.97)
ELF Index
A: 0.82 (0.73 to 0.92)
B: 0.91 (0.82 to 1.0)
Hepatic transit time
A: 0.71 (0.59 to 0.84)
B: 0.83 (0.69 to 0.97)
Schneider, 2006196Germany83Fibrosis (Ishak ≥3): 57%
Cirrhosis (Ishak 5 or 6): 23%
Age: 48 years
Female: 51%
Genotype 1: 84%
Cirrhosis (Ishak 5–6)APRI: 0.71 (CI not reported)Portal venous flow: 0.80 (CI not reported)
Testa, 2006209Italy75Fibrosis (Ishak ≥3): 49%
Cirrhosis (Ishak 5 or6): 12%
Age: 50 years
Female: 32%
Genotype 1b: 43%
All elevated aminotransferases
No alcohol abuse
Fibrosis (Ishak ≥3)Fibrosis (Ishak ≥3)
APRI: 0.72 (0.60 to 0.82)
Platelet-spleen diameter ratio: 0.74 (0.63 to 0.84)
Fibrosis model 1: 0.80 (0.69 to 0.88)a

APRI = aspartate aminotransferase (AST) to platelets ratio; AUROC = area under the receiver operating characteristic curve; CI = confidence interval

a

Based on sample used to derive the risk prediction instrument.

From: Results

Cover of Screening for Hepatitis C Virus Infection in Adults
Screening for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 69.
Chou R, Cottrell EB, Wasson N, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.